CL-218,872 EU

6 - 52

Discover CL-218,872 – The Next Generation Sedative

Introduction CL-218,872, a groundbreaking sedative-hypnotic offering unparalleled efficacy in inducing sleep and reducing anxiety. Unlike traditional benzodiazepines, CL-218,872 targets specific GABA A receptors, ensuring a focused approach with fewer side effects. Ideal for research and therapeutic applications, it’s a beacon of hope for those seeking reliable and safe sedation.

Ce produit est également disponible en Capsule et Gouttes pour faciliter la recherche.

Tous les produits de l'UE peuvent être expédiés uniquement dans les pays de l'UE.

Toutes les drogues de synthèse vendues sur ce site sont destinées à la recherche et aux applications médico-légales.

 

Product Overview:

CL-218,872 is a novel sedative and hypnotic compound. Unlike traditional benzodiazepines, it belongs to a unique class of nonbenzodiazepine hypnotics. The compound is particularly noted for its selective action on the GABA A receptor, specifically targeting the α1 subtype.

Chemical and Pharmacological Properties:

The molecular structure of CL-218,872 differentiates it from benzodiazepines, contributing to its unique pharmacological profile. Its action as a partial agonist at the GABA A receptor sites leads to sedative, anxiolytic, anticonvulsant, and amnestic effects, with a reduced risk of dependency compared to traditional benzodiazepines.

Posologie et administration :

The optimal dosage of CL-218,872 varies depending on the intended use and the subject’s physiology. In research settings, dosages are carefully controlled and monitored.

Therapeutic Effects:

CL-218,872 is primarily used in research for its sedative and hypnotic effects. It has shown potential in studies for inducing sleep and reducing anxiety, with a faster onset and shorter duration of action, making it advantageous for specific therapeutic applications.

Side Effects and Harm Reduction:

Like all sedative-hypnotics, CL-218,872 can cause side effects such as dizziness, confusion, and motor impairment. Long-term use or misuse can lead to tolerance and dependence. Its safety profile, however, indicates a lower risk of these adverse effects compared to traditional benzodiazepines. Harm reduction strategies involve controlled administration, monitoring for adverse reactions, and avoiding use with other central nervous system depressants.

Comparative Analysis:

In comparison to other hypnotics like triazolam or zolpidem, CL-218,872 offers a unique balance of efficacy and safety, making it a subject of interest in both pharmacological research and potential clinical use.

Pourquoi acheter CL-218,872 EU from RECHEMCO?

★ Nous avons une longue expérience commerciale sur le marché, ce qui vous permet de bénéficier de notre expérience.
★ CL-218,872 a été testé et vérifié.
★ We accept various payment methods such as Bitcoin, Monero, many other cryptocurrencies and bank wire.

Ce que vous recevrez en achetant CL-218,872 EU from RECHEMCO?

- Un sachet en aluminium scellé contenant des produits de la plus haute qualité CL-218,872 EU
• White powder
• 98-99% Purity

Quantité

50mg, 100mg, 250mg, 500mg, 1g

Avis

Il n’y a pas encore d’avis.

Soyez le premier à laisser votre avis sur “CL-218,872 EU”

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

GAGNEZ EN JOUANT !

  • Tentez votre chance et gagnez un code de réduction
  • 1 tour gratuit tous les 15 jours
  • Pas de triche ! Veuillez utiliser uniquement votre véritable adresse électronique.
  • RAPPEL : La validité du code de réduction est de 7 jours.
Tentez votre chance !
Jamais
Rappeler plus tard
Non merci